Cost of management of invasive growth hormone-secreting macroadenoma.
about
Clinical, quality of life, and economic value of acromegaly disease controlAssessment of real-world usage of lanreotide AUTOGEL 120 in Polish acromegalic patients - results from the prospective 12-month phase of Lanro-Study.Emerging drugs for acromegaly.Decision-tree model for health economic comparison of two long-acting somatostatin receptor ligand devices in France, Germany, and the UK.Cost of clinical management of acromegaly in Spain.
P2860
Cost of management of invasive growth hormone-secreting macroadenoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Cost of management of invasive growth hormone-secreting macroadenoma.
@en
type
label
Cost of management of invasive growth hormone-secreting macroadenoma.
@en
prefLabel
Cost of management of invasive growth hormone-secreting macroadenoma.
@en
P2860
P356
P1476
Cost of management of invasive growth hormone-secreting macroadenoma
@en
P2093
C Varela da Costa
P2860
P2888
P304
P356
10.1007/BF03346346
P577
2007-07-01T00:00:00Z